Research progress on PD-1/PD-L1 inhibitors in tumor immuno-therapy
10.3969/j.issn.1000-8179.2015.24.803
- VernacularTitle:PD-1/PD-L1抑制剂在肿瘤免疫治疗中的研究进展
- Author:
Yintao YE
;
Chen WANG
;
Bei SUN
- Publication Type:Journal Article
- Keywords:
immunotherapy;
anti-tumor;
PD-1 inhibitors;
PD-L1 inhibitors
- From:
Chinese Journal of Clinical Oncology
2015;(24):1178-1182
- CountryChina
- Language:Chinese
-
Abstract:
Tumor immunotherapy is highlighted in tumor studies and has a remarkable curative effect on tumors. Programmed cell death-1 (PD-1), which is mainly expressed in activated T and B cells, is an important immune inhibitory molecule. Its ligand PD-L1 could be highly expressed in cancer cells, and the PD-1 pathway shows sustained activation in a tumor micro-environment. PD-1/PD-L1 inhibitors can block the combination of PD-1 and PD-L1, inhibit negative to regulatory signals, and restore the activity of T cells, thereby enhancing immune response. Recent studies showed that PD-1 and PD-L1 inhibitors have been effective in many tumor types. This review summarizes PD-1/PD-L1 inhibitors and their clinical effects on different tumor types.
